These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

433 related articles for article (PubMed ID: 28216072)

  • 41. Impact of Belimumab on Organ Damage in Systemic Lupus Erythematosus.
    Urowitz MB; Aranow C; Asukai Y; Bass DL; Bruce IN; Chauhan D; Dall'Era M; Furie R; Fox NL; Gilbride JA; Hammer A; Ginzler EM; Gonzalez-Rivera T; Levy RA; Merrill JT; Quasny H; Roth DA; Stohl W; van Vollenhoven R; Wallace DJ; Petri M
    Arthritis Care Res (Hoboken); 2022 Nov; 74(11):1822-1828. PubMed ID: 35439360
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Baseline predictors of systemic lupus erythematosus flares: data from the combined placebo groups in the phase III belimumab trials.
    Petri MA; van Vollenhoven RF; Buyon J; Levy RA; Navarra SV; Cervera R; Zhong ZJ; Freimuth WW;
    Arthritis Rheum; 2013 Aug; 65(8):2143-53. PubMed ID: 23754628
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Efficacy and safety of belimumab for the treatment of refractory childhood-onset systemic lupus erythematosus: A single-center, real-world, retrospective study.
    Wang D; Shan C; Liu J; Zhang R; Zhu G; Gao T; Chang H; Gao S; Bai C; Nie N; Zhang Q; Lin Y
    Front Immunol; 2022; 13():1067721. PubMed ID: 36591249
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Effects of belimumab, a B lymphocyte stimulator-specific inhibitor, on disease activity across multiple organ domains in patients with systemic lupus erythematosus: combined results from two phase III trials.
    Manzi S; Sánchez-Guerrero J; Merrill JT; Furie R; Gladman D; Navarra SV; Ginzler EM; D'Cruz DP; Doria A; Cooper S; Zhong ZJ; Hough D; Freimuth W; Petri MA;
    Ann Rheum Dis; 2012 Nov; 71(11):1833-8. PubMed ID: 22550315
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Clinical, laboratory and health-related quality of life correlates of Systemic Lupus Erythematosus Responder Index response: a post hoc analysis of the phase 3 belimumab trials.
    Furie R; Petri MA; Strand V; Gladman DD; Zhong ZJ; Freimuth WW;
    Lupus Sci Med; 2014; 1(1):e000031. PubMed ID: 25396065
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Assessments of fatigue and disease activity in patients with systemic lupus erythematosus enrolled in the Phase 2 clinical trial with blisibimod.
    Petri MA; Martin RS; Scheinberg MA; Furie RA
    Lupus; 2017 Jan; 26(1):27-37. PubMed ID: 27353505
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Disease-modifying effect and long-term safety of belimumab in patients with systemic lupus erythematosus: A single-center retrospective study.
    Nakai T; Fukui S; Sawada H; Ikada Y; Tamaki H; Kishimoto M; Okada M
    Lupus; 2023 Nov; 32(13):1518-1527. PubMed ID: 37858981
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Patient- and Physician-reported Satisfaction With Systemic Lupus Erythematosus Treatment in US Clinical Practice.
    Pascoe K; Lobosco S; Bell D; Hoskin B; Chang DJ; Pobiner B; Ramachandran S
    Clin Ther; 2017 Sep; 39(9):1811-1826. PubMed ID: 28803702
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Development and Validation of a Novel Evidence-Based Lupus Multivariable Outcome Score for Clinical Trials.
    Abrahamowicz M; Esdaile JM; Ramsey-Goldman R; Simon LS; Strand V; Lipsky PE
    Arthritis Rheumatol; 2018 Sep; 70(9):1450-1458. PubMed ID: 29648686
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Systemic lupus erythematosus exacerbation following cessation of belimumab treatment.
    Furer V; Zisman D; Pokroy-Shapira E; Molad Y; Elkayam O; Paran D
    Scand J Rheumatol; 2016; 45(2):103-6. PubMed ID: 26515057
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Charlson Comorbidity Index Is Related to Organ Damage in Systemic Lupus Erythematosus: Data from KORean lupus Network (KORNET) Registry.
    Kim SK; Choe JY; Lee SS
    J Rheumatol; 2017 Apr; 44(4):452-458. PubMed ID: 28298561
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Long-term open-label continuation study of the safety and efficacy of belimumab for up to 7 years in patients with systemic lupus erythematosus from Japan and South Korea.
    Tanaka Y; Bae SC; Bass D; Curtis P; Chu M; DeRose K; Ji B; Kurrasch R; Lowe J; Meizlik P; Roth DA
    RMD Open; 2021 Jul; 7(2):. PubMed ID: 34215703
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Belimumab for the treatment of systemic lupus erythematosus.
    Jordan N; D'Cruz DP
    Expert Rev Clin Immunol; 2015 Feb; 11(2):195-204. PubMed ID: 25543845
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Belimumab in the treatment of Portuguese Systemic Lupus Erythematosus patients: a real-life multicenter study.
    Fernandes BM; Barreira S; Fonseca JE; Cunha M; Santos MJ; Gonçalves N; Fernandes AL; Rodrigues J; Fontes T; Costa L; Bernardes M
    Acta Reumatol Port; 2020; 45(3):170-176. PubMed ID: 33139681
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Autoantibodies' titre modulation by anti-BlyS treatment in systemic lupus erythematosus.
    Cavazzana I; Kumar R; Pozzari C; Ottaviani R; Fredi M; Piantoni S; Andreoli L; Tincani A; Franceschini F
    Lupus; 2019 Aug; 28(9):1074-1081. PubMed ID: 31296140
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Characterization of B- and T-Cell Compartment and B-Cell Related Factors Belonging to the TNF/TNFR Superfamily in Patients With Clinically Active Systemic Lupus Erythematosus: Baseline BAFF Serum Levels Are the Strongest Predictor of Response to Belimumab after Twelve Months of Therapy.
    Piantoni S; Regola F; Masneri S; Merletti M; Lowin T; Airò P; Tincani A; Franceschini F; Andreoli L; Pongratz G
    Front Pharmacol; 2021; 12():666971. PubMed ID: 34093196
    [No Abstract]   [Full Text] [Related]  

  • 57. Belimumab Decreases Autophagy and Citrullination in Peripheral Blood Mononuclear Cells from Patients with Systemic Lupus Erythematosus.
    Colasanti T; Spinelli FR; Barbati C; Ceccarelli F; Scarpa S; Vomero M; Alessandri C; Valesini G; Conti F
    Cells; 2022 Jan; 11(2):. PubMed ID: 35053379
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Systemic Lupus Erythematosus (SLE) Responder Index response is associated with global benefit for patients with SLE.
    Furie R; Wang L; Illei G; Drappa J
    Lupus; 2018 May; 27(6):955-962. PubMed ID: 29460699
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Smoking and Its Association With Morbidity in Systemic Lupus Erythematosus Evaluated by the Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index: Preliminary Data and Systematic Review.
    Montes RA; Mocarzel LO; Lanzieri PG; Lopes LM; Carvalho A; Almeida JR
    Arthritis Rheumatol; 2016 Feb; 68(2):441-8. PubMed ID: 26359794
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Frequency and predictors for early-achieved lupus low disease activity state in systemic lupus erythematosus patients treated with telitacicept or belimumab: A real-life, single-center observational study.
    Fan C; Yang T; Zheng S; Liao X; Xie R; Chen S; Li J
    Front Immunol; 2024; 15():1423035. PubMed ID: 38947321
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 22.